Targeting the MAGE-A3 Protein in Lung Cancer
Silvia Novello, MD, PhD, from the University of Turin, Italy, gives an overview of immunotherapy and the targeting of the MAGE-A3 protein in lung cancer.
Silvia Novello, MD, PhD, Assistant Professor, Thoracic Oncology Unit, University of Turin, San Luigi Hospital, Orbassano, Italy, gives an overview of immunotherapy and the targeting of the MAGE-A3 protein in lung cancer.
Though lung cancer is not as immunogenic as some other cancers, Novello says, immunotherapy is still growing in the field. With regards to the amount of disease present, early stage disease is the best situation to use a vaccine.
Clinical Pearls
A vaccine targeting the MAGE-A3 protein is in development for early disease. The trial has completed accrual and is ongoing, with about 35-55% of patients being MAGE-A3-positive. Novello believes the trial results will be clear and positive.
- Lung cancer is not as immunogenic as some other cancers
- Early stage disease is the best situation to use vaccines
- A vaccine targeting the MAGE-A3 protein is in development
Survivorship Care Promotes Evidence-Based Approaches for Quality of Life and Beyond
March 21st 2025Frank J. Penedo, PhD, explains the challenges of survivorship care for patients with cancer and how he implements programs to support patients’ emotional, physical, and practical needs.
Read More
